Measles Infection Clinical Trial
Official title:
A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine
Overall objective: To conduct a randomised controlled trial (RCT) to examine whether an
early two-dose measles vaccination (MV) strategy at 4 and 9 months will reduce child
mortality compared with the WHO strategy of one dose of MV at 9 months.
Specific hypotheses Hypothesis I) Two doses of MV at 4 and 9 months compared with the
standard dose of MV at 9 months will reduce mortality by 30% between 4 months and 5 years of
age1. As in a previous trial it is expected that the beneficial effect is strongest for
girls.
Hypothesis II) Children receiving MV at 4 months in the presence of maternal measles
antibodies (MatAb) will have 35% lower mortality between 4 months and 5 years of age than
children receiving MV at 4 months with no detectable MatAb.
Implications: These hypotheses are based on a previous RCT showing strong beneficial effects
of providing an early measles vaccine, in particular among children with MatAb.
n/a
Allocation: Randomized, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06153979 -
Investigation of Immune Amnesia Following Measles Infection in Select African Regions
|